Plasma Proteomics 2025: Potential Realized and the Insights Drug Developers Can Expect

Plasma proteomics has long held great potential for both biomarker discovery and clinical development, providing a minimally invasive means to measure tissue biology, identify early biomarkers of disease, and monitor disease progression and therapeutic response over time. However, the complexity of the human plasma proteome has precluded broad measure via plasma proteomics and limited its utility for drug development, until now.

This webinar will explore the recent technological developments finally allowing drug developers to extract maximal biological insight from the plasma proteome, with deeper coverage and with greater efficiency for large-scale studies. We will look at methodologies that are overcoming previous trade-offs in measurement speed, sensitivity, and specificity; enrichment techniques enabling detection of biologically/clinically relevant low-abundance proteins in plasma; and why approaches that capture protein isoforms as well as exosomal and membrane-bound proteins have become so critical in 2025.

Importantly, we will review the types of robust analyses that can now be enabled in plasma and share examples of how this data is contributing to the advancement of target identification and precision medicine.

You’ll learn about:

• Prior limitations to harnessing the full discovery potential of the human plasma proteome
• Innovative methods revolutionizing plasma proteomics in 2025
• Actionable insights for drug discovery and development that can be gained through the robust measure and analysis of the breadth of proteins and proteoforms in plasma